JNJ 17299425

Drug Profile

JNJ 17299425

Alternative Names: JNJ-17299425

Latest Information Update: 02 Apr 2013

Price : $50

At a glance

  • Originator Johnson & Johnson
  • Class Neuropsychotherapeutics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Brain injuries

Most Recent Events

  • 01 Aug 2008 Discontinued - Phase-II for Brain injuries in Belgium (IV)
  • 01 Aug 2008 Discontinued - Phase-II for Brain injuries in France (IV)
  • 01 Aug 2008 Johnson & Johnson terminates phase II trial in Brain injuries in Belgium & France due to reprioritisation of company activities (NCT01814982)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top